肿瘤学

Our scientists and oncologists strive to give patients improved treatment outcomes and a life beyond cancer by developing therapies that elevate the standards of care.

\r\n"}}" id="text-e39c79dc53" class="cmp-text">

我们的科学家和肿瘤学家努力给患者改善治疗结果和癌症之外的生活通过开发的标准疗法,提高护理。

建筑专业知识解决最棘手的癌症

Our scientific research has led to critical discoveries in the treatment of blood cancer. Now we’re expanding our knowledge to help treat solid tumors, which represent more than 90% of cancers that affect people.
\r\n
\r\nWe leverage our deep understanding of human biology and cutting-edge research technologies to find new ways to improve the lives of people with cancer.

\r\n"}}" id="text-59459b05ee" class="cmp-text">

我们的科学研究导致血液癌症的关键发现治疗。现在我们扩大我们的知识,帮助治疗实体肿瘤,代表超过90%的癌症影响的人。

我们利用我们的深刻理解人类生物学和前沿研究技术寻找新的方法来提高癌症患者的生命。


技术的进步和理解发生在过去的十年里真的使我们思考不同的疾病。这不仅仅是跟上潮流,这是大胆的和冒险的科学进展。

克里斯谢霆锋博士。
执行董事、肿瘤学、发现研究,AbbVie

研究兴趣

We focus on creating targeted medicines that either impede the reproduction of cancer cells or enable their death. We achieve this through immuno-oncology approaches, tumor antigen targeting, and taking advantage of specific tumor dependencies. Our research interests include:

\r\n
    \r\n
  • Identifying and targeting mechanisms that allow tumor cells to proliferate and survive, including under-explored forms of regulated cell death, such as necroptosis and ferroptosis
    \r\n
    \r\n
  • \r\n
  • Investigating how to re-energize T cells so that they can retain their fitness and continue to destroy tumor cells
    \r\n
    \r\n
  • \r\n
  • Advancing the use of Antibody Drug Conjugates (ADCs) to target and deliver potent toxins and targeted agents directly to cancer cells
    \r\n
    \r\n
  • \r\n
  • Creating new technologies to improve the efficacy of bispecific biologics in treating both solid tumors and blood cancers, enabling the development of therapies with highly targeted potential
    \r\n
    \r\n
  • \r\n
  • Innovating in the field of targeted protein degradation by designing protein degraders that bind to a protein of interest and trigger its proteasomal degradation
    \r\n
    \r\n
  • \r\n
  • Developing CAR-T cell therapies that attack cancers with healthy donor immune cells engineered to target and kill tumor cells while being resistant to host immune system rejection
  • \r\n
\r\n"}}" id="text-32c461d558" class="cmp-text">

我们专注于开发靶向药物阻止癌细胞的繁殖或使他们的死亡。我们通过immuno-oncology实现这一方法,肿瘤抗原定位,利用特定肿瘤依赖性。我们的研究兴趣包括:

  • 识别和定位机制,使肿瘤细胞增殖和生存,包括监管有待进一步研究形式的细胞死亡,如necroptosis ferroptosis

  • 研究如何重振T细胞,这样他们就可以保持他们的健康和继续破坏肿瘤细胞

  • 推进使用抗体药物配合(adc)目标和提供有效的毒素和直接向肿瘤细胞靶向制剂

  • 创造新的技术来提高双特异性生物制剂的疗效在治疗实体肿瘤和血液癌症,使与具有高度针对性的疗法的发展潜力狗万正网地址

  • 设计创新领域的目标蛋白质降解蛋白降能器感兴趣的蛋白结合并引发其蛋白酶体降解

  • 发展与健康的捐赠者CAR-T细胞疗法攻击癌症免疫细胞工程目标并杀死肿瘤细胞,抵抗宿主免疫系统排斥
相关内容
Increasing awareness about blood cancers

\r\n"}}" id="text-8be2644ff9" class="cmp-text">

增加对血液癌症




主题

肿瘤学领域

We are focusing on finding answers that transform the way cancer is treated. We want to find better, longer-lasting results across blood cancers and solid tumors. Our culture of curiosity drives us to uncover new solutions.

\r\n"}}" id="text-c19848face" class="cmp-text">

我们专注于寻找答案,改变了治疗癌症的方法。我们想要找到更好的,更持久的结果在血液癌症和实体肿瘤。我们的文化的好奇心驱使我们发现新的解决方案。


血液癌症

Blood cancer is a disease that impacts blood forming tissues (such as bones marrow) and inhibits the body's ability to fight off infection. Leukemia, lymphoma, and myeloma are the most common forms of blood cancer that are seen in patients.

\r\n"}}" id="text-4276ffe210" class="cmp-text">

血液癌症是一种疾病,影响血液形成组织(如骨骨髓),抑制身体抵御感染的能力。白血病、淋巴瘤和骨髓瘤是最常见的形式的血液癌症的病人。


血液癌症

实体肿瘤

Common solid tumor types include sarcomas and carcinomas. Oftentimes, these are treated with surgery. We are working to create new treatments for these diseases that can develop anywhere, including the bones, muscles, and organs.

\r\n"}}" id="text-3c6ea5868d" class="cmp-text">

常见的固体肿瘤类型包括癌和肉瘤。通常,这些都是用手术治疗。我们正在创造一个新的治疗这些疾病,可以在任何地方发展,包括骨骼、肌肉和器官。